Amerise Biosciences Ltd (AMERISE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Amerise Biosciences Ltd on NSE and BSE, with an AI summary of each filing.
PFA
Financial Result · 30 Oct 2026, 10:29 pm
Amerise Biosciences Reports Q2 FY27 Net Loss Amid Zero Operating Revenue Amerise Biosciences reported zero revenue from operations for the quarter ended 30th Sep'26, down from total income of Rs 6.75 lakh in Q2 FY26. Total expenses stood at Rs 5.76 lakh versus Rs 10.98 lakh YoY and Rs 8.14 lakh QoQ. Consequently, net loss widened YoY to Rs 5.76 lakh from Rs 4.23 lakh in Q2 FY26, though narrowing QoQ from Rs 8.14 lakh. EPS stood at negative Rs 0.01. For H1 FY27, net loss widened to Rs 13.91 lakh compared to Rs 5.04 lakh YoY.
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 30 Oct 2026, 10:11 pm
Amerise Biosciences Reports Q2 FY27 Results with Widened Net Loss Amerise Biosciences reported zero revenue from operations for Q2 ended 30th Sep'26, compared to nil revenue and other income of ₹6.75 lakhs in Q2 ended 30th Sep'25. Net loss for the quarter expanded to ₹5.76 lakhs versus a net loss of ₹4.23 lakhs YoY, driven by employee benefit expenses of ₹0.82 lakhs and other operating expenses of ₹4.94 lakhs. For H1 ended 30th Sep'26, net loss stood at ₹13.91 lakhs against ₹5.04 lakhs YoY. EPS for the quarter was ₹(0.01).
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd
Acquisition/ Disposal of Shares · 30 Oct 2026, 9:33 pm
Snehjeev Ventures and PACs Increase Stake in Amerise Biosciences to 13.02% Snehjeev Ventures Pvt. Ltd., along with Persons Acting in Concert (PACs), acquired 18,342 equity shares (0.03% stake) of Amerise Biosciences Ltd. via open market purchases on 28th Oct'26. Following this transaction, the collective holding of the acquirer and PACs increased from 8,584,734 shares (12.99%) to 8,603,076 shares, representing 13.02% of the company's total voting capital of Rs. 6.61 crore (comprising 66,06,900 equity shares of Rs. 10 each). The acquirer group belongs to the non-promoter category.
Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 30 Oct 2026, 5:30 am
Amerise Biosciences Schedules Board Meeting for Q2 FY27 Results Amerise Biosciences Limited has notified BSE that its Board of Directors will meet on 30th Oct'26. The primary agenda is to consider, approve, and take on record the company's unaudited financial results for the second quarter and half year ended 30th Sep'26, alongside other general business matters.
PFA
Others (Uncategorized) · 10 Oct 2026, 9:23 pm
Amerise Biosciences Announces Corporate Website Update to BSE Amerise Biosciences Limited (formerly Amradeep Industries Limited) notified BSE Limited on 10th Oct'26 regarding an update to its official corporate website. The company announced its new domain address as www.amerisebiosciencesltd.bar, requesting the exchange to update its records and replace the previous website details accordingly.
PFA
Annual General Meeting · 24 Sept 2026, 10:11 pm
Amerise Biosciences Shareholders Approve Key AGM Resolutions With 100% Voting Favor Amerise Biosciences Limited announced the voting results of its 41st AGM held on 24th Sep'26. Shareholders approved all ordinary resolutions with 100% votes cast in favor across 12,675,378 polled shares (19.185% turnout of 66,069,000 total shares). Key approvals included the adoption of audited financial statements for the fiscal year ended 31st Mar'26 along with reports of directors and auditors, as well as the appointment of Mr. Albert Hines (DIN: 10742692) as Wholetime Director and Chief Financial Officer. All participating votes came exclusively from public non-institutional shareholders.
PFA
Annual General Meeting · 24 Sept 2026, 9:57 pm
Amerise Biosciences Approves Financial Statements and Appoints Whole-time Director and CFO Amerise Biosciences Limited transacted and approved key resolutions at its 41st Annual General Meeting held on 24th Sep'26. Shareholders approved the adoption of audited financial statements for the financial year ended 31st Mar'26, along with reports from directors and auditors. Additionally, shareholders cleared an ordinary resolution appointing Mr. Albert Hines (DIN: 10742692) as Whole-time Director and Chief Financial Officer of the company. Detailed voting results under Regulation 44(3) are being submitted separately.
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial ....
Others (Uncategorized) · 01 Sept 2026, 10:17 pm
PFA
Annual General Meeting · 01 Sept 2026, 10:10 pm
Amerise Biosciences to Hold 41st AGM; Seeks Approval for WTD & CFO Appointment Amerise Biosciences (AMERISE) will hold its 41st Annual General Meeting on 24th Sep'26. Key agenda items include adopting the FY26 audited financials and seeking shareholder approval for the appointment of Mr. Albert Hines as Whole Time Director (WTD) & Chief Financial Officer (CFO). The appointment is effective from 02nd Feb'26 for a three-year term with nil remuneration. The record date for e-voting eligibility is 17th Sep'26. The Register of Members will be closed from 17th Sep'26 to 24th Sep'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:21 pm
Snehjeev Ventures Acquires Stake in Amerise Biosciences, Crossing 11% Holding Snehjeev Ventures Pvt. Ltd., along with persons acting in concert (PACs), acquired 76,725 equity shares of Amerise Biosciences Ltd. through an open market transaction on 14-Aug-26. This purchase increased their collective holding from 7,215,959 shares (10.92%) to 7,292,684 shares (11.04%), crossing the 11% threshold. The acquirers are not part of the promoter group. The target company, Amerise Biosciences, is listed on BSE Limited. The total voting capital post-acquisition stands at Rs 6,60,69,000, comprising 66,06,900 equity shares of Rs. 10 each.
PFA
Financial Result · 03 Aug 2026, 10:57 pm
Amerise Biosciences Reports Net Loss for Q1 FY27 Amerise Biosciences reported a net loss of Rs. 8.14 lacs for Q1 FY27 (ended 30-Jun-26), a significant decline from a net profit of Rs. 6.13 lacs in Q4 FY26 and widening from a loss of Rs. 0.81 lacs in Q1 FY26. The company recorded zero revenue from operations, compared to Rs. 7.92 lacs QoQ and Rs. 6.37 lacs YoY. The loss was driven by total expenses of Rs. 8.14 lacs. Basic and diluted EPS for the quarter stood at Rs. (0.01).
PFA
Financial Result · 03 Aug 2026, 10:56 pm
Amerise Biosciences Q1 FY27 Results Show Significant Net Loss Amerise Biosciences reported a net loss of Rs. 8.14 lacs for the quarter ended 30th Jun'26, a sharp decline from the Rs. 6.13 lacs profit in the prior quarter (Q4 FY26) and the Rs. 0.81 lacs loss YoY. The company recorded zero revenue from operations, compared to Rs. 7.92 lacs QoQ and Rs. 6.37 lacs YoY. Total expenses were Rs. 8.14 lacs, a significant increase from Rs. 1.79 lacs QoQ. The basic and diluted EPS for the quarter stood at Rs. (0.01).
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of ....
Outcome · 03 Aug 2026, 10:52 pm
Amerise Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBITDA: -8.1 (-904.9% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): 0.0 (Loss to Profit YoY | -7740 bps QoQ) ■ PAT: -8.1 (-904.9% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.01 (Profit to Loss QoQ)
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 29 Jul 2026, 10:55 pm
Snehjeev Ventures and PACs Increase Stake in Amerise Biosciences Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) acquired 28,000 equity shares (0.04% stake) in Amerise Biosciences via an open market transaction. This acquisition, which crossed the 9% threshold on 20-Jul'26, increased their total holding from 5,934,355 shares (8.98%) to 5,962,355 shares (9.02%). The acquirer group does not belong to the promoter group. The target company’s equity share capital remains at Rs. 6,60,69,000, comprising 66,06,900 shares of Rs. 10 each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 22 Jul 2026, 10:49 pm
Snehjeev Ventures & PACs Cross 9% Stake in Amerise Biosciences Snehjeev Ventures Pvt Ltd, along with persons acting in concert (PACs), increased its holding in Amerise Biosciences Ltd to 9.02% of total capital on 20th Jul'26. The entity acquired 28,000 equity shares (0.04% stake) via an open market transaction. Prior to this, their combined holding was 5,934,355 shares, or 8.98%. Following the acquisition, the total holding stands at 5,962,355 shares. Snehjeev Ventures and the PACs are not part of the promoter group. Amerise Biosciences' total equity capital remains at Rs. 6.61 Cr.
Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 03 Aug 2026, 5:30 am
Amerise Biosciences Board Meeting Set for Aug 3rd to Approve Q1 Results Amerise Biosciences Ltd. has scheduled a Board of Directors meeting on 03 Aug'26. The primary agenda is to consider and approve the company's un-audited financial results for the first quarter ending 30 Jun'26. The meeting will also address any other matters with the board's permission.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 17 Jul 2026, 4:11 pm
Snehjeev Ventures & PACs Reduce Stake in Amerise Biosciences Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) sold 318,285 shares (0.48% of total capital) of Amerise Biosciences in an open market transaction on 15 Jul'26. Following the sale, their combined shareholding decreased from 6,153,446 shares (9.31%) to 5,835,161 shares (8.83%). The disclosure was made under SEBI's takeover regulations. The acquirer group does not belong to the promoter group. The total paid-up capital of the company remains at Rs. 6.61 crore.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 17 Jul 2026, 3:58 pm
Snehjeev Ventures Reduces Stake in Amerise Biosciences Below 9% Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) sold 318,285 equity shares of Amerise Biosciences Ltd. through an open market transaction on 15th Jul'26. This disposal represents 0.48% of the company's total share capital. Following the sale, their combined shareholding has decreased from 6,153,446 shares (9.31%) to 5,835,161 shares (8.83%), falling below the 9% threshold. The acquirers are not part of the promoter group. The transaction was disclosed under SEBI SAST Regulations, 2011.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 09 Jul 2026, 4:47 pm
Snehjeev Ventures & PACs Increase Stake in Amerise Biosciences Beyond 9% Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) acquired 38,574 equity shares (0.06% stake) of Amerise Biosciences Ltd via an open market transaction on 06-Jul'26. This acquisition increased their total holding from 5,933,892 shares (8.98%) to 5,972,466 shares (9.04%), crossing the 9% threshold. The acquirer group does not belong to the promoter/promoter group. The target company's total voting capital remains at Rs. 6,60,69,000, comprising 66,06,900 equity shares of Rs. 10 each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 05 Jun 2026, 9:26 pm
Snehjeev Ventures & PACs Cross 7% Stake in Amerise Biosciences Snehjeev Ventures Pvt Ltd, with persons acting in concert, increased its stake in Amerise Biosciences Ltd to 7.04% on 04-Jun'26. The entity acquired 32,000 equity shares (0.05% stake) via an open market transaction. This purchase took their total holding from 4,618,896 shares (6.99%) to 4,650,896 shares (7.04%), crossing the 7% regulatory threshold. The acquirer does not belong to the promoter group.
PFA
Financial Result · 05 May 2026, 11:11 pm
Amerise Biosciences Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 7.9 (-57.9% YoY | +76.4% QoQ) ■ EBITDA: 6.1 (-42.1% YoY | +532.0% QoQ) ■ EBITDA Margin (%): 77.4 (+2107 bps YoY | +5580 bps QoQ) ■ PAT: 6.1 (-42.1% YoY | +532.0% QoQ) ■ EPS (INR): 0.01 (-50.0% YoY)
This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Tuesday 5th May, 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....
Outcome · 05 May 2026, 11:03 pm
Amerise Biosciences Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 7.9 (-57.9% YoY | +76.4% QoQ) ■ EBITDA: 6.1 (-42.1% YoY | +532.0% QoQ) ■ EBITDA Margin (%): 77.4 (+2107 bps YoY | +5580 bps QoQ) ■ PAT: 6.1 (-42.1% YoY | +532.0% QoQ) ■ EPS (INR): 0.01 (-50.0% YoY)
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 05 May 2026, 4:43 pm
Snehjeev Ventures & PACs Cross 5% Stake in Amerise Biosciences Snehjeev Ventures Pvt. Ltd., along with Persons Acting in Concert (PACs), acquired 560,000 equity shares (0.85% stake) in Amerise Biosciences Ltd. through an open market transaction. This purchase, dated 24th Apr'26, increased their total holding from 2,969,664 shares (4.49%) to 3,529,664 shares (5.34%), crossing the 5% substantial acquisition threshold. The acquirer does not belong to the promoter group. The target company's total voting capital remains at Rs. 6,60,69,000, comprising 66,06,900 equity shares of Rs. 10 each.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 29 Apr 2026, 5:41 pm
Snehjeev Ventures & PACs Cross 5% Stake in Amerise Biosciences Snehjeev Ventures Pvt Ltd, along with persons acting in concert (PACs), acquired 3,529,664 equity shares in Amerise Biosciences Ltd. This transaction, effective 24-Apr-26, increased their collective holding from 4.49% to 5.34% of the company's total capital. The acquisition was conducted via the open market. This disclosure is made under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, for crossing the 5% ownership threshold. Snehjeev Ventures and the PACs do not belong to the promoter group.
Amerise Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 05 May 2026, 5:30 am
Amerise Biosciences Board Meeting Set for 5th May'26 to Approve FY26 Results Amerise Biosciences (BSE: 531681) has scheduled a Board of Directors meeting on 5th May'26. The primary agenda is to consider and approve the audited standalone financial results for the quarter and fiscal year ending on 31st Mar'26. The board will also review the accompanying auditor's report. Any other matters may be discussed with the board's permission. This meeting is crucial for the release of the company's full-year earnings and performance data for FY26.